Michael E. Berens

Dr. Michael E. Berens

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2018 in Science
Verified
Journal Article
Closed access
PDF file
RPRalph B. Puchalski
Ralph B. Puchalski
NSNameeta Shah
Nameeta Shah
JMJeremy Miller
Jeremy Miller
RDRachel Dalley
Rachel Dalley
SNSteve R. Nomura
Steve R. Nomura
GFGreg D. Foltz
Greg D. Foltz
Anatomically correct tumor genomics: Glioblastoma is the most lethal form of human brain cancer. The genomic alterations and gene expression profiles characterizing this tumor type have been widely studied. Puchalski et al. created the Ivy Glioblastoma Atlas, a freely available online resource for the research community. The atlas, a collaborative effort between bioinformaticians and pathologists, maps molecular features of glioblastomas, such as transcriptional signatures, to histologically defined anatomical regions of the tumors. The relationships identified in this atlas, in conjunction with associated databases of clinical and genomic information, could provide new insights into the pathogenesis, diagnosis, and treatment of glioblastoma. Science , this issue p. 660

26 January 2007 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
MNM. Nakada
M. Nakada
SNS. Nakada
S. Nakada
TDT. Demuth
T. Demuth
NTN. L. Tran
N. L. Tran
DHD. B. Hoelzinger
D. B. Hoelzinger
MBMichael E. Berens
Michael E. Berens

2 January 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
WYWei Yang
Wei Yang
NWNicole M. Warrington
Nicole M. Warrington
STSara J. Taylor
Sara J. Taylor
PWPaula Whitmire
Paula Whitmire
ECEduardo Carrasco
Eduardo Carrasco
JRJoshua B. Rubin
Joshua B. Rubin
Male and female glioblastomas are biologically distinct, and improving outcomes may require sex-specific approaches to treatment.

1 January 2005 in Neoplasia
Verified
Journal Article
Open access
DHDominique B. Hoelzinger
Dominique B. Hoelzinger
LMLuigi Mariani
Luigi Mariani
JWJoachim Weis
Joachim Weis
TWTanja Woyke
Tanja Woyke
TBTheresa J. Berens
Theresa J. Berens
MBMichael E. Berens
Michael E. Berens
The invasive phenotype of glioblastoma multiforme (GBM) is a hallmark of malignant process, yet molecular mechanisms that dictate this locally invasive behavior remain poorly understood. Gene expression profiles of human glioma cells were assessed from laser capture-microdissected GBM cells collected from paired patient tumor cores and white matter-invading cell populations. Changes in gene expression in invading GBM cells were validated by quantitative reverse transcription polymerase chain reaction (QRT-PCR) and immunohistochemistry in an independent sample set. QRT-PCR confirmed the differential expression in 19 of 21 genes tested. Immunohistochemical analyses of autotaxin (ATX), ephrin B3, B-cell lymphoma-w (BCLW), and protein tyrosine kinase 2 beta showed them to be expressed in invasive glioma cells. The known GBM markers, insulin-like growth factor binding protein 2 and vimentin, were robustly expressed in the tumor core. A glioma invasion tissue microarray confirmed the expression of ATX and BCLW in invasive cells of tumors of various grades. GBM phenotypic and genotypic heterogeneity is well documented. In this study, we show an additional layer of complexity: transcriptional differences between cells of tumor core and invasive cells located in the brain parenchyma. Gene products supporting invasion may be novel targets for manipulation of brain tumor behavior with consequences on treatment outcome.

19 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
NVNicholas A Vitanza
Nicholas A Vitanza
AWAshley L. Wilson
Ashley L. Wilson
WHWenjun Huang
Wenjun Huang
KSKristy Seidel
Kristy Seidel
CBChristopher Brown
Christopher Brown
JPJulie R. Park
Julie R. Park
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) tumors, we designed B7-H3–specific chimeric antigen receptor (CAR) T cells, confirmed their preclinical efficacy, and opened BrainChild-03 (NCT04185038), a first-in-human phase I trial administering repeated locoregional B7-H3 CAR T cells to children with recurrent/refractory CNS tumors and DIPG. Here, we report the results of the first three evaluable patients with DIPG (including two who enrolled after progression), who received 40 infusions with no dose-limiting toxicities. One patient had sustained clinical and radiographic improvement through 12 months on study. Patients exhibited correlative evidence of local immune activation and persistent cerebrospinal fluid (CSF) B7-H3 CAR T cells. Targeted mass spectrometry of CSF biospecimens revealed modulation of B7-H3 and critical immune analytes (CD14, CD163, CSF-1, CXCL13, and VCAM-1). Our data suggest the feasibility of repeated intracranial B7-H3 CAR T-cell dosing and that intracranial delivery may induce local immune activation. Significance: This is the first report of repeatedly dosed intracranial B7-H3 CAR T cells for patients with DIPG and includes preliminary tolerability, the detection of CAR T cells in the CSF, CSF cytokine elevations supporting locoregional immune activation, and the feasibility of serial mass spectrometry from both serum and CSF. This article is highlighted in the In This Issue feature, p. 1

1 March 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
RVRachael A. Vaubel
Rachael A. Vaubel
STShulan Tian
Shulan Tian
DRDioval Remonde
Dioval Remonde
MSMark A. Schroeder
Mark A. Schroeder
AMAnn C. Mladek
Ann C. Mladek
JSJann N. N Sarkaria
Jann N. N Sarkaria
Purpose: Glioblastoma is the most frequent and lethal primary brain tumor. Development of novel therapies relies on the availability of relevant preclinical models. We have established a panel of 96 glioblastoma patient-derived xenografts (PDX) and undertaken its genomic and phenotypic characterization. Experimental Design: PDXs were established from glioblastoma, IDH-wildtype (n = 93), glioblastoma, IDH-mutant (n = 2), diffuse midline glioma, H3 K27M-mutant (n = 1), and both primary (n = 60) and recurrent (n = 34) tumors. Tumor growth rates, histopathology, and treatment response were characterized. Integrated molecular profiling was performed by whole-exome sequencing (WES, n = 83), RNA-sequencing (n = 68), and genome-wide methylation profiling (n = 76). WES data from 24 patient tumors was compared with derivative models. Results: PDXs recapitulate many key phenotypic and molecular features of patient tumors. Orthotopic PDXs show characteristic tumor morphology and invasion patterns, but largely lack microvascular proliferation and necrosis. PDXs capture common and rare molecular drivers, including alterations of TERT, EGFR, PTEN, TP53, BRAF, and IDH1, most at frequencies comparable with human glioblastoma. However, PDGFRA amplification was absent. RNA-sequencing and genome-wide methylation profiling demonstrated broad representation of glioblastoma molecular subtypes. MGMT promoter methylation correlated with increased survival in response to temozolomide. WES of 24 matched patient tumors showed preservation of most genetic driver alterations, including EGFR amplification. However, in four patient–PDX pairs, driver alterations were gained or lost on engraftment, consistent with clonal selection. Conclusions: Our PDX panel captures the molecular heterogeneity of glioblastoma and recapitulates many salient genetic and phenotypic features. All models and genomic data are openly available to investigators.